Bryan Roberts

Background

Bryan Roberts is a General Partner at Venrock, the venture capital firm founded as the formalized investment arm of the Rockefeller family ¹. He joined Venrock in 1997 as a Kauffman Fellow (Class 3), serving his fellowship under mentor Anthony Evnin at Venrock’s New York office ². He has been based in Palo Alto, California throughout most of his career ¹.

Roberts holds a B.A. from Dartmouth College (inducted Phi Beta Kappa, chemistry) and a Ph.D. in Chemistry and Chemical Biology from Harvard University ². He transitioned directly from completing his doctoral research into venture capital at Venrock ².

Roberts has been named to the Forbes Midas List of top tech investors twelve times between 2008 and 2020, with Forbes ranking him the #1 healthcare investor multiple times during that period ²³. In 2019, the National Venture Capital Association honored him with the Excellence in Healthcare Innovation Award at its annual Leadership Gala ⁴. The Aspen Institute designated him a Henry Crown Fellow in 2006 ².

He is a co-founder of Castlight Health (2008), which he incubated at Venrock’s offices alongside Todd Park (co-founder of athenahealth and later U.S. Chief Technology Officer) and Giovanni Colella ⁵. Castlight went public in 2014 with a full-diluted market cap in excess of $3 billion on its first day of trading ⁶. Roberts also co-founded Devoted Health (2017) as its founding investor and co-founder alongside Todd Park, Ed Park, and Bob Kocher ⁷.

Nine of Roberts’ portfolio companies have reached a valuation of $1 billion or more ¹.

Stated Thesis

(Self-reported. See Inferred Thesis for analysis of actual investment behavior.)

Roberts publicly describes his investment approach as contrarian and conviction-driven, focused on healthcare companies tackling large problems via orthogonal approaches that most investors initially dismiss. He has stated: “I get the most satisfaction out of doing things that, when we start with them, nobody else likes. I spend years going, ‘I don’t know why everyone in the world doesn’t love this.’” ⁸

He explicitly rejects pattern-matching as an investment framework: “For most decisions truly crucial to company/investment success, the application of pattern recognition is a red herring; and often it is derived from intellectual laziness.” He argues that “disruption doesn’t come in the form of +1 improvements; it comes when you decide to do something others believe is either impossible or silly.” ⁹

On what he looks for in founders, Roberts has identified three criteria: (1) considerable intelligence; (2) humility and the ability to listen, which he describes as an ability to admit what they don’t know and do what they can to learn; and (3) access to a substantial market opportunity where the technology is actually ready ¹⁰.

He has stated a specific aversion to companies whose primary customer is the pharmaceutical industry, noting their “data needs…are too fragmented,” and to wearables, stating Venrock avoids them “because we have not seen the persistence of usage” ¹¹.

On fund allocation, Roberts has said: “We’re pretty bottoms-up allocation driven; we invest based on the projects we find and fall in love with. Life sciences usually ends up being around 30% to 40% [of capital invested].” ¹²

Inferred Thesis

Based on 26 verified portfolio investments spanning Roberts’ career at Venrock from 1998 to 2024, the following patterns emerge. Note: this sample represents a subset of his full investment activity; qualitative descriptions are used where sample size does not support reliable percentages.

Sector breakdown (26 verified investments): - Life sciences / therapeutics / genomics: 13 of 26 (50%) — Illumina, Ironwood Pharmaceuticals, Ikaria, Sirna Therapeutics, Receptos, Fate Therapeutics, Ariosa Diagnostics, Encoded Therapeutics, Kelonia Therapeutics, Moonlight Bio, Interdict Bio, 10x Genomics, Inscripta - Health IT / digital health / health services: 11 of 26 (42%) — athenahealth, Castlight Health, Devoted Health, Aledade, Lyra Health, Included Health (Grand Rounds + Doctor on Demand), Suki, SmithRx, Element Biosciences, Zeltiq, PHC Global - Other / hybrid: 2 of 26 (8%) — Stride Health, Intarcia Therapeutics

Stage distribution: Primarily seed and Series A entry points, with consistent follow-through into later rounds. Roberts has led seed and Series A rounds (Illumina Series A at $8.5M, Devoted Health $7.4M seed, Aledade $4.5M seed, Suki $20M Series A), but has also led much larger rounds (SmithRx $60M Series C). Check size range of $2M–$40M is consistent across his verified investments ¹³.

Two distinct sub-portfolios:

• Life sciences deep science (1998–2010s): Genomics tools (Illumina, 10x Genomics, Element Biosciences), gene therapy/editing (Encoded Therapeutics, Kelonia Therapeutics, Inscripta), and pharmaceutical plays (Ironwood, Receptos, Sirna, Fate Therapeutics). These are consistently pre-revenue, science-first companies started by researchers from top academic institutions.

• Health IT and care delivery (2008–present): Health IT infrastructure (athenahealth, Castlight Health), value-based care enablement (Aledade, Devoted Health), behavioral/mental health (Lyra Health), AI-powered clinical tools (Suki), pharmacy benefits (SmithRx), and care navigation (Included Health). Roberts has explicitly noted his shift toward digital health around 2012 ⁸: “I am hugely intellectually selfish. I work on stuff that is interesting to me from an intellectual perspective.”

Notable co-investment patterns: Frequently co-invests with ARCH Venture Partners (Illumina, Encoded Therapeutics, Inscripta), Foresite Capital (Element Biosciences), Greylock Partners (Lyra Health), and Oak HC/FT (Devoted Health). Within Venrock, Roberts frequently co-invests with partner Bob Kocher on health services deals (Devoted Health, Lyra Health, Aledade).

Founder profile patterns: Roberts repeatedly backs founders with deep domain expertise from elite academic institutions or from prior successful healthcare companies. Portfolio founders include researchers from Scripps Research Institute (Receptos), MIT/Stanford (Kelonia), and entrepreneurs with prior exits (Todd Park, who co-founded athenahealth before Castlight and Devoted Health).

Notable gap between stated and inferred thesis: Roberts explicitly avoids pharma-focused companies and wearables, and these categories are absent from verified portfolio data — consistent with stated thesis. However, despite describing himself as primarily seed/Series A, several verified investments are at Series B or later (Ariosa Diagnostics Series C, SmithRx Series B and C), suggesting meaningful deployment at growth stages.

Portfolio outcomes: Of 26 verified investments, at least 9 have returned at or above $1B in enterprise value: Illumina (public, NASDAQ: ILMN), athenahealth (acquired by Veritas/Everest, ~$6.5B), Ikaria (acquired by Madison Dearborn, $1.6B), Sirna Therapeutics (acquired by Merck, $1.1B), Castlight Health (IPO, $3B+ on first day), Receptos (acquired by Celgene, $7.2B), 10x Genomics (public, NASDAQ: TXG), Ironwood Pharmaceuticals (public, NASDAQ: IRWD), Ariosa Diagnostics (acquired by Roche, 2014) ³¹⁴¹⁵.

Portfolio

This table represents 25 of Roberts’ publicly confirmed investments. Years marked with ~ are approximate based on company founding dates and press coverage. Roberts’ full investment history at Venrock spans 28+ years and likely includes additional undisclosed investments.

In Their Own Words

On contrarian satisfaction (Boston Biotech Watch Q&A, January 11, 2017):

“I get the most satisfaction out of doing things that, when we start with them, nobody else likes. I spend years going, ‘I don’t know why everyone in the world doesn’t love this.’” ⁸

On why data science doesn’t drive investment decisions (Boston Biotech Watch Q&A, January 11, 2017):

“We do not use it at all in choosing deals… Our investments are made in things where there are way more variables than equations.” ⁸

On his intellectual motivation for investing (Boston Biotech Watch Q&A, January 11, 2017):

“I am hugely intellectually selfish. I work on stuff that is interesting to me from an intellectual perspective.” ⁸

On pattern recognition as a constraint (Fortune op-ed, April 27, 2017):

“For most decisions truly crucial to company/investment success, the application of pattern recognition is a red herring; and often it is derived from intellectual laziness.” ⁹

On disruption (Fortune op-ed, April 27, 2017):

“Disruption doesn’t come in the form of +1 improvements; it comes when you decide to do something others believe is either impossible or silly.” ⁹

On first-principles thinking (Fortune op-ed, April 27, 2017):

“For the most impactful decisions, it is crucial not to apply some model but to accept the ambiguity that comes with doing new things, and to undertake the hard thinking from first principles required to construct the best path forward.” ⁹

On investment models (Fortune, March 2014):

“I actively try not to follow any model set… Long before pivot became cliché, companies like Athenahealth evolved from service businesses into IT businesses.” ³

On what makes a good founder (Fortune Brainstorm Health conference, May 2017):

“One mistake I’ve made is backing a company where there is a market need but the technology is not ready for prime time.” ¹⁰ “Most of the companies were not successful on the first thing they started with. It was the second or third thing that took off.” ¹⁰

On scaling in digital health (MobiHealthNews, August 20, 2015):

“In digital health, people have business plans that show how to go from zero to $10 million or $20 million in revenue. But what comes after that? Where is the plan to get to $250 million?” ¹¹

On avoiding wearables (MobiHealthNews, August 20, 2015):

Roberts avoids wearables “because we have not seen the persistence of usage.” ¹¹

On Venrock’s investment allocation (TechCrunch, January 8, 2021):

“We’re pretty bottoms-up allocation driven; we invest based on the projects we find and fall in love with. Life sciences usually ends up being around 30% to 40% [of capital invested].” ¹²

On Kelonia Therapeutics (press release, April 28, 2022):

“Kelonia is combining the two crucial elements required to develop truly novel medicines: breakthrough biology and an exceptional team. Michael Birnbaum’s industrially robust platform affords a targeting specificity log orders better than anything else out there and the team has a stellar track record for translating groundbreaking scientific gene therapy discoveries into viable products that are transformative for patients.” ²⁹

On Suki (Series D press release, October 2024):

“Since our seed investment in Suki, the company has grown exponentially by securing strategic partnerships with leading health systems and healthtech companies, and demonstrating meaningful impact to all stakeholders, from clinicians to administrators. Suki is well on its way to becoming the de facto AI platform for healthcare and we are proud to support it as it continues its rapid growth.” ³³

On Element Biosciences (press release, June 18, 2019):

“Materially improved pricing and performance benchmarks for genetic analysis, in an easy to use package, would dramatically increase use cases and thereby propel our understanding of biology to new levels. This is Element’s mission.” ²⁶

On Illumina (press release, December 17, 1998):

“We are very pleased to join such an outstanding group of scientists at Illumina. As internationally recognized experts in genomics, immunology, molecular biology, analytical and combinatorial chemistry, information processing, artificial olfaction and fiber optic sensors, these individuals bring a vast amount of knowledge to the company.” ¹⁶

What Founders Say

Todd Park, Co-Founder and Executive Chairman of Devoted Health (and former U.S. Chief Technology Officer), posted on LinkedIn in October 2021 about Roberts’ contribution to Devoted Health: Park expressed profound gratitude for “the sheer amount of love, energy, and time that Bryan and Bob poured into Devoted,” calling it “an extraordinary gift” to have Roberts in the trenches with the Devoted team as they built the company ³⁴.

No other independently sourced founder testimonials about working with Bryan Roberts were found at time of research. Roberts appears on the Venrock “Running Through Walls” podcast with portfolio founders, but episode transcripts were not accessible for verbatim quote extraction.

Connections

• Co-founder, Castlight Health — alongside Todd Park (former U.S. CTO, co-founder of athenahealth) and Giovanni Colella ⁵
• Co-founder, Devoted Health — alongside Todd Park (Executive Chairman), Ed Park (President), and Bob Kocher (founding CMO) ⁷
• Board member, Ironwood Pharmaceuticals (IRWD) — Roberts has served as Chairman of Ironwood Pharmaceuticals ¹
• Board member, Kelonia Therapeutics — serves alongside Michael Birnbaum (MIT), Michael Fischbach (Stanford), Kevin Friedman, and Bob More (Alta Partners) ²⁹
• Board member, Element Biosciences — joined board September 2017 ²⁶
• Board member, Encoded Therapeutics — confirmed board member ³⁵
• Board member, Tisento Therapeutics — confirmed board member ³²
• Kauffman Fellow, Class 3 — fellowship under mentor Anthony Evnin at Venrock ²
• Henry Crown Fellow, Aspen Institute (2006) ²
• Frequent co-investor with ARCH Venture Partners — Illumina, Encoded Therapeutics, Inscripta ¹⁶²⁸²⁴
• Frequent co-investor with Bob Kocher (Venrock partner) — Devoted Health, Lyra Health, Aledade; co-authors annual Fortune healthcare predictions ³⁶

Sources